CKPT

Checkpoint Therapeutics (CKPT)

About Checkpoint Therapeutics (CKPT)

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.

Details

Daily high

$3.76

Daily low

$3.33

Price at open

$3.35

52 Week High

$4.50

52 Week Low

$1.38

Market cap

183.1M

Dividend yield

0.00%

Volume

2.3M

Avg. volume

2.5M

P/E ratio

-2.60

Checkpoint Therapeutics News